MeSH D003316 - corneal diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D005128:Eye diseases
0 Companies
0 Drugs
Success rate
D003316:
Corneal diseases
D003317:Hereditary corneal dystrophies
0 Companies
0 Drugs
Success rate
D003318:Corneal opacity
0 Companies
0 Drugs
Success rate
D007634:Keratitis
D007640:Keratoconus
0 Companies
0 Drugs
Success rate
D014141:Trachoma
D015715:Corneal edema
0 Companies
0 Drugs
Success rate
D016510:Corneal neovascularization
0 Companies
0 Drugs
Success rate
D055954:Corneal endothelial cell loss
0 Companies
0 Drugs
Success rate
D057108:Corneal wavefront aberration
0 Companies
0 Drugs
Success rate
D057129:Iridocorneal endothelial syndrome
0 Companies
0 Drugs
Success rate
D065306:Corneal injuries
0 Companies
0 Drugs
Success rate
D000092423:Limbal stem cell deficiency
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Santen | Ciclosporin | Ikervis | 2015-03-19 |
Clinical Trials
Historical Success Rate
Phase 1
100%9/9
Phase 2
0%0/9
Phase 3
100%3/3
Approved: 3Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use